سعر بيماستريم 40 مجم 2025

Rameda rosuvastatin 40 mg film-coated tablets, pack of 10.

• Reduce the risk of major adverse cardiovascular events in adults at increased risk for CV eventsPopulation: AdultsDailyMed (U.S. NLM)
• Adjunct to diet and exercise to reduce LDL-C in adults with primary hypercholesterolemiaPopulation: AdultsDailyMed (U.S. NLM)
• Adjunct to diet and exercise to reduce LDL-C and slow progression of atherosclerosis in adultsPopulation: AdultsDailyMed (U.S. NLM)

• Most frequent adverse reactions (>=2%): headache, nausea, myalgia, asthenia, constipation.International label, same formulation · DailyMed (U.S. NLM)

• Acute liver failure or decompensated cirrhosis.International label, same formulation · DailyMed (U.S. NLM)
• Hypersensitivity to rosuvastatin or any excipients (rash, pruritus, urticaria, angioedema reported).International label, same formulation · DailyMed (U.S. NLM)

• Myopathy and rhabdomyolysis: risk factors include age >=65, uncontrolled hypothyroidism, renal impairment, interacting drugs, higher dose, and Asian ancestry. Discontinue if markedly elevated CK or myopathy suspected.International label, same formulation · DailyMed (U.S. NLM)
• Hepatic dysfunction: increases in serum transaminases reported; rare fatal/non-fatal hepatic failure. Consider liver enzymes before initiation and as clinically indicated.International label, same formulation · DailyMed (U.S. NLM)
• Immune-mediated necrotizing myopathy (IMNM) rarely reported with statins; discontinue if suspected.International label, same formulation · DailyMed (U.S. NLM)

• CyclosporineMajorDo not exceed rosuvastatin 5 mg once daily with cyclosporine (exposure increased ~7-fold).DailyMed (U.S. NLM)
• GemfibrozilMajorAvoid concomitant use; if unavoidable initiate 5 mg and do not exceed 10 mg once daily.DailyMed (U.S. NLM)
• WarfarinModerateObtain INR before starting rosuvastatin; monitor frequently until stable after initiation/titration/discontinuation.DailyMed (U.S. NLM)

• Discontinue when pregnancy is recognized, or consider ongoing therapeutic need. May cause fetal harm based on mechanism (decreases cholesterol synthesis). Available observational data have not identified a drug-associated risk of major congenital malformations; data on miscarriage insufficient.International label, same formulation · DailyMed (U.S. NLM)
• Present in human milk (limited case reports). Breastfeeding not recommended during treatment because of potential serious adverse reactions in the breastfed infant.International label, same formulation · DailyMed (U.S. NLM)

• Rosuvastatin: Competitive inhibition of HMG-CoA reductase reduces hepatic cholesterol synthesis and increases LDL-receptor expression, lowering plasma LDL-C.